Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2496)	4/28/2009 3:05:46 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PRXL was up 24% earlier, but is up only 14$ at present. <g> The stock opened on an UG as it tries to close the Apr21 DG. Today's volume of 3,804,780 is about 4x its ADV and the largest in the last 10 days. bigcharts.marketwatch.com The stock is responding to the 3rdQ results that were released yesterday after the market closed. finance.yahoo.com Bernard

To: Jibacoa who wrote (2496)	4/6/2010 10:15:34 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AVNR is up up 5.65% as it tries to deal with the March 29 H at $2.72 <g> Volume is more than half its ADV. bigcharts.marketwatch.com It announced today that it will present three scientific posters featuring details of Zenvia's safety and efficacy data from the PIII STAR at the American Academy of Neurology Annual Meeting in Toronto, April 10 – 17, 2010. The first poster will be presented a week from today.<g> The spike in August last year to $4.09 was when it reported positive results of the PIII STAR for Zenvia in patients with pseudobulbar affect. bigcharts.marketwatch.com AVNR was able to trim its loss a little on the 1stQ in spite of lower revenues, but the loss for 2010 is still expected around $0.30 vs. $0,28 last Yr. However, the EE for 2011 are around $0.20 on the black column.AVNR has no significant LTD but has been burning its cash at a good clip.<g> The short ratio came down some in the last month, but is still around 6x its ADV,<g> The ACTAY is $8.90 and it seems that with some good news the stock could spike to $5, but I think I will still keep my present target at just $4.<g> bigcharts.marketwatch.com Bernard